НовостиBenzingaMorgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13 Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13 Benzinga 2026.10.21 15:58 (GMT+0) Открыть на Benzinga Другие новости